TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01844856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV to maintain the blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV to maintain the blind.
Study: NCT04171635

Intervention type: RADIATION
Intervention: Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)
Description: Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.

Intervention type: RADIATION
Intervention: Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)
Description: Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.

Intervention type: RADIATION
Intervention: R2* Magnetic Resonance Imaging (MRI)
Description: Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique

Intervention type: RADIATION
Intervention: R2* Magnetic Resonance Imaging (MRI)
Description: Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
Study: NCT03869385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albutein® 200 g/L or Plasbumin® 20
Description: The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
Study: NCT02406469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption milk Tetra Pak
Description: Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral consumption milk Tetra Pak
Description: Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
Study: NCT01185600

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unwashed RBC
Description: There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
Study: NCT04003259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle management programme
Description: The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
Study: NCT03483051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate
Description: Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Potassium Chloride
Description: Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
Study: NCT00890591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
Description: olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
Study: NCT01543282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)
Description: Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)
Description: Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
Study: NCT02907216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Squarekids
Description: Three doses administered subcutaneously in the upper arm or thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Squarekids
Description: Three doses administered subcutaneously in the upper arm or thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two doses administered orally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Two doses administered orally
Study: NCT03935867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-PROFET
Description: An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
Study: NCT00983333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Time to Talk CARDIO website
Description: This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Time to Talk CARDIO website
Description: This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
Study: NCT01301066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg QD
Study: NCT03232021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule administered 1 hour prior to the surgical operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 75mg
Description: Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
Study: NCT00540657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX282-B
Description: 250mg capsule, twice daily, 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, twice daily, 13 weeks
Study: NCT02242136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FORNET
Study: NCT03232021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 150 mg
Description: Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
Study: NCT01624454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laxabon
Description: 4 l PEG solution split dose cleansing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CitraFleet
Description: Small volume osmotic bowelcleansing
Study: NCT03740711

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial venting
Description: The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial venting
Description: The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
Study: NCT02088047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProFoveate
Description: ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
Study: NCT00492908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helistent Titan2 (Titanium coated stent)
Description: Titan2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndeavorTM (Zotarolimus-Eluting Stent)
Description: Endeavor
Study: NCT00309985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: androgen-deprivation therapy
Description: LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen-deprivation therapy
Description: LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT04525911

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: serology test for COVID-19
Description: a serology test will be performed at M3
Study: NCT03416972

Intervention type: RADIATION
Intervention: Standard platinum-based chemoradiotherapy
Description: Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
Study: NCT00516906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: 2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transparent Adhesive Dressing
Description: Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
Study: NCT05405348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The patients did not eat anything during hemodialysis.
Study: NCT05300828

Intervention type: DRUG
Intervention: Genexl PM
Description: Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
Study: NCT04032236

Intervention type: OTHER
Group type: OTHER
Intervention: caffeine
Description: At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group

Intervention type: OTHER
Group type: OTHER
Intervention: caffeine
Description: At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
Study: NCT04898569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferric carboxymaltose injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush
Description: placebo
Study: NCT00371345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
Study: NCT03712514

Intervention type: OTHER
Group type: OTHER
Intervention: Destabilization of the upper cervical spine by Cervistab
Description: Simulate a situation of destabilization of the cervical spine with Cervistab

Intervention type: OTHER
Group type: OTHER
Intervention: Destabilization of the upper cervical spine by Cervistab
Description: Simulate a situation of destabilization of the cervical spine with Cervistab
Study: NCT04197661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Study: NCT05479656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: 8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
Study: NCT02345837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial sampling
Description: injury to the endometrium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: ovulation induction by 100mg clomiphene citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: ovulation induction by 100mg clomiphene citrate
Study: NCT01682395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection and anastomosis
Description: Resection of sigmoid colon with primary anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection and anastomosis
Description: Resection of sigmoid colon with primary anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection and colostomy
Description: Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesosigmoidopexy
Description: Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
Study: NCT02288156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: via nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: via nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: via nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: via nasal spray
Study: NCT02593253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback Bundle
Description: The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bi-weekly audit and feedback emails
Description: The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
Study: NCT01502410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study: NCT00371345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg
Description: Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
Study: NCT03234374

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INL-001 (bupivacaine HCl collagen implant)
Description: 3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
Study: NCT03319329

Intervention type: DEVICE
Intervention: Indirect Calorimetry
Description: REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
Study: NCT03160872

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti Mullerian Hormone Measurement
Description: Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
Study: NCT02627196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO® System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Study: NCT03686462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-based interactive treadmill training
Description: During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Treadmill training without VR-based interaction
Description: Treadmill training without VR-based interaction
Study: NCT04443205

Intervention type: OTHER
Intervention: Data record
Description: Data record

Intervention type: OTHER
Intervention: Data record
Description: Data record

Intervention type: OTHER
Intervention: Data record
Description: Data record
Study: NCT00979264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive quality improvement tools
Description: Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.